Synergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by Oppenheimer

Synergy Pharmaceuticals (NASDAQ:SGYP)‘s stock had its “hold” rating reaffirmed by Oppenheimer in a research report issued on Sunday.

Other research analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Synergy Pharmaceuticals in a report on Thursday, February 1st. Cantor Fitzgerald restated a “buy” rating on shares of Synergy Pharmaceuticals in a report on Thursday, February 1st. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Friday, February 16th. Finally, BidaskClub upgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $8.08.

Shares of NASDAQ SGYP opened at $1.89 on Friday. The stock has a market cap of $466.34 million, a PE ratio of -1.85 and a beta of 1.22. Synergy Pharmaceuticals has a 1 year low of $1.42 and a 1 year high of $4.84. The company has a quick ratio of 2.71, a current ratio of 3.09 and a debt-to-equity ratio of -3.01.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. The firm had revenue of $8.59 million during the quarter, compared to analysts’ expectations of $11.18 million. During the same period last year, the company earned ($0.30) earnings per share. The business’s revenue was up 776.5% on a year-over-year basis. research analysts anticipate that Synergy Pharmaceuticals will post -0.57 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in SGYP. Wells Fargo & Company MN boosted its stake in Synergy Pharmaceuticals by 18.2% in the third quarter. Wells Fargo & Company MN now owns 219,676 shares of the biopharmaceutical company’s stock valued at $638,000 after acquiring an additional 33,802 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Synergy Pharmaceuticals by 11.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 1,051,408 shares of the biopharmaceutical company’s stock valued at $2,345,000 after acquiring an additional 106,222 shares during the last quarter. Exane Derivatives boosted its stake in Synergy Pharmaceuticals by 79.4% in the fourth quarter. Exane Derivatives now owns 107,979 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 47,774 shares during the last quarter. Malaga Cove Capital LLC boosted its stake in Synergy Pharmaceuticals by 1,115.8% in the fourth quarter. Malaga Cove Capital LLC now owns 97,266 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 89,266 shares during the last quarter. Finally, Granite Investment Partners LLC purchased a new position in Synergy Pharmaceuticals in the fourth quarter valued at about $632,000. Institutional investors and hedge funds own 51.70% of the company’s stock.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply